DELFI Diagnostics

DELFI Diagnostics is a biotechnology company founded in 2019 that focuses on early cancer detection through a blood-based liquid biopsy platform.

Utilizing a proprietary technology called "fragmentomics," DELFI analyzes unique patterns of DNA fragmentation in cell-free DNA from blood samples. This innovative approach captures cancer signals that traditional methods may overlook, making it suitable for both early cancer screening and drug development research. The company offers a range of services, including the DELFI Method, which employs machine-learning algorithms for accurate cancer detection, and specialized tests like FirstLook Lung for early lung cancer detection in at-risk individuals. DELFI also provides multi-cancer screening capabilities and partners with biopharma companies for biomarker discovery and treatment monitoring. With dual headquarters in Palo Alto, CA, and Baltimore, MD, DELFI Diagnostics is committed to enhancing oncology care through advanced, non-invasive testing solutions.